Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165566500> ?p ?o ?g. }
- W3165566500 endingPage "e421" @default.
- W3165566500 startingPage "e410" @default.
- W3165566500 abstract "Despite advances in the treatment of Hodgkin lymphoma with the introduction of PET-adapted regimens, practical challenges prevent more widespread use of these approaches. The ECHELON-1 study assessed the safety and efficacy of front-line A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in patients with stage III or IV classical Hodgkin lymphoma. The primary analysis showed improved modified progression-free survival with A+AVD. We present an updated analysis of ECHELON-1 at 5 years, an important landmark for this patient population.ECHELON-1 was an international, open-label, randomised, phase 3 trial done at 218 clinical sites, including hospitals, cancer centres, and community clinics, in 21 countries. Previously untreated patients (≥18 years with an Eastern Cooperative Oncology Group performance status of ≤2) with stage III or IV classical Hodgkin lymphoma were randomly assigned (1:1) to receive A+AVD (brentuximab vedotin, 1·2 mg/kg of bodyweight, doxorubicin 25 mg/m2 of body surface area, vinblastine 6 mg/m2, and dacarbazine 375 mg/m2) or ABVD (doxorubicin 25 mg/m2, bleomycin 10 U/m2, vinblastine 6 mg/m2, and dacarbazine 375 mg/m2) intravenously on days 1 and 15 of each 28-day cycle for up to six cycles. Stratification factors included region (Americas vs Europe vs Asia) and International Prognostic Score risk group (low, intermediate, or high risk). The primary endpoint was modified progression-free survival; this 5-year update includes analysis of progression-free survival as per investigator assessment in the intention-to-treat population, which was an exploratory endpoint, although the 5-year analysis was not prespecified in the protocol. This trial is registered with ClinicalTrials.gov (NCT01712490) and EudraCT (2011-005450-60), and is ongoing.Between Nov 19, 2012, and Jan 13, 2016, 1334 patients were randomly assigned to receive A+AVD (n=664) or ABVD (n=670). At a median follow-up of 60·9 months (IQR 52·2-67·3), 5-year progression-free survival was 82·2% (95% CI 79·0-85·0) with A+AVD and 75·3% (71·7-78·5) with ABVD (hazard ratio [HR] 0·68 [95% CI 0·53-0·87]; p=0·0017). Among PET-2-negative patients, 5-year progression-free survival was higher with A+AVD than with ABVD (84·9% [95% CI 81·7-87·6] vs 78·9% [75·2-82·1]; HR 0·66 [95% CI 0·50-0·88]; p=0·0035). 5-year progression-free survival for PET-2-positive patients was 60·6% (95% CI 45·0-73·1) with A+AVD versus 45·9% (32·7-58·2) with ABVD (HR 0·70 [95% CI 0·39-1·26]; p=0·23). Peripheral neuropathy continued to improve or resolve over time with both A+AVD (375 [85%] of 443 patients) and ABVD (245 [86%] of 286 patients); more patients had ongoing peripheral neuropathy in the A+AVD group (127 [19%] of 662) than in the ABVD group (59 [9%] of 659). Fewer secondary malignancies were reported with A+AVD (19 [3%] of 662) than with ABVD (29 [4%] of 659). More livebirths were reported in the A+AVD group (n=75) than in the ABVD group (n=50).With 5 years of follow-up, A+AVD showed robust and durable improvement in progression-free survival versus ABVD, regardless of PET-2 status, and a consistent safety profile. On the basis of these findings, A+AVD should be preferred over ABVD for patients with previously untreated stage III or IV classical Hodgkin lymphoma.Millennium Pharmaceuticals (a wholly owned subsidiary of Takeda Pharmaceutical Company), and Seagen." @default.
- W3165566500 created "2021-06-07" @default.
- W3165566500 creator A5005446802 @default.
- W3165566500 creator A5006117950 @default.
- W3165566500 creator A5011398209 @default.
- W3165566500 creator A5012342629 @default.
- W3165566500 creator A5013717203 @default.
- W3165566500 creator A5015840872 @default.
- W3165566500 creator A5016655102 @default.
- W3165566500 creator A5017873196 @default.
- W3165566500 creator A5022658681 @default.
- W3165566500 creator A5024844183 @default.
- W3165566500 creator A5026265919 @default.
- W3165566500 creator A5029918677 @default.
- W3165566500 creator A5038596323 @default.
- W3165566500 creator A5052962596 @default.
- W3165566500 creator A5053811082 @default.
- W3165566500 creator A5056728544 @default.
- W3165566500 creator A5058956866 @default.
- W3165566500 creator A5059488532 @default.
- W3165566500 creator A5059729547 @default.
- W3165566500 creator A5060314041 @default.
- W3165566500 creator A5060741746 @default.
- W3165566500 creator A5067329171 @default.
- W3165566500 creator A5068152076 @default.
- W3165566500 creator A5071885891 @default.
- W3165566500 creator A5085712310 @default.
- W3165566500 creator A5090442154 @default.
- W3165566500 creator A5091882595 @default.
- W3165566500 date "2021-06-01" @default.
- W3165566500 modified "2023-10-16" @default.
- W3165566500 title "Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial" @default.
- W3165566500 cites W1974114089 @default.
- W3165566500 cites W1974950819 @default.
- W3165566500 cites W1975834243 @default.
- W3165566500 cites W1976281058 @default.
- W3165566500 cites W2001261680 @default.
- W3165566500 cites W2023306536 @default.
- W3165566500 cites W2103004443 @default.
- W3165566500 cites W2133487516 @default.
- W3165566500 cites W2165308914 @default.
- W3165566500 cites W2415747453 @default.
- W3165566500 cites W2469052042 @default.
- W3165566500 cites W2623378930 @default.
- W3165566500 cites W2756060398 @default.
- W3165566500 cites W2765462510 @default.
- W3165566500 cites W2775803967 @default.
- W3165566500 cites W2784654265 @default.
- W3165566500 cites W2792836052 @default.
- W3165566500 cites W2891621703 @default.
- W3165566500 cites W2909797130 @default.
- W3165566500 cites W2954226397 @default.
- W3165566500 cites W2963365727 @default.
- W3165566500 cites W3033765098 @default.
- W3165566500 cites W3045410974 @default.
- W3165566500 cites W3080882593 @default.
- W3165566500 doi "https://doi.org/10.1016/s2352-3026(21)00102-2" @default.
- W3165566500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34048680" @default.
- W3165566500 hasPublicationYear "2021" @default.
- W3165566500 type Work @default.
- W3165566500 sameAs 3165566500 @default.
- W3165566500 citedByCount "72" @default.
- W3165566500 countsByYear W31655665002021 @default.
- W3165566500 countsByYear W31655665002022 @default.
- W3165566500 countsByYear W31655665002023 @default.
- W3165566500 crossrefType "journal-article" @default.
- W3165566500 hasAuthorship W3165566500A5005446802 @default.
- W3165566500 hasAuthorship W3165566500A5006117950 @default.
- W3165566500 hasAuthorship W3165566500A5011398209 @default.
- W3165566500 hasAuthorship W3165566500A5012342629 @default.
- W3165566500 hasAuthorship W3165566500A5013717203 @default.
- W3165566500 hasAuthorship W3165566500A5015840872 @default.
- W3165566500 hasAuthorship W3165566500A5016655102 @default.
- W3165566500 hasAuthorship W3165566500A5017873196 @default.
- W3165566500 hasAuthorship W3165566500A5022658681 @default.
- W3165566500 hasAuthorship W3165566500A5024844183 @default.
- W3165566500 hasAuthorship W3165566500A5026265919 @default.
- W3165566500 hasAuthorship W3165566500A5029918677 @default.
- W3165566500 hasAuthorship W3165566500A5038596323 @default.
- W3165566500 hasAuthorship W3165566500A5052962596 @default.
- W3165566500 hasAuthorship W3165566500A5053811082 @default.
- W3165566500 hasAuthorship W3165566500A5056728544 @default.
- W3165566500 hasAuthorship W3165566500A5058956866 @default.
- W3165566500 hasAuthorship W3165566500A5059488532 @default.
- W3165566500 hasAuthorship W3165566500A5059729547 @default.
- W3165566500 hasAuthorship W3165566500A5060314041 @default.
- W3165566500 hasAuthorship W3165566500A5060741746 @default.
- W3165566500 hasAuthorship W3165566500A5067329171 @default.
- W3165566500 hasAuthorship W3165566500A5068152076 @default.
- W3165566500 hasAuthorship W3165566500A5071885891 @default.
- W3165566500 hasAuthorship W3165566500A5085712310 @default.
- W3165566500 hasAuthorship W3165566500A5090442154 @default.
- W3165566500 hasAuthorship W3165566500A5091882595 @default.
- W3165566500 hasConcept C126322002 @default.
- W3165566500 hasConcept C141071460 @default.
- W3165566500 hasConcept C143998085 @default.
- W3165566500 hasConcept C2776232574 @default.
- W3165566500 hasConcept C2776305933 @default.